1. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J. 2002; 66(6):529–533.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Madden JA. Role of the vascular endothelium and plaque in acute ischemic stroke. Neurology. 2012; 79(13 Suppl 1):S58–S62.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Suganya N, Bhakkiyalakshmi E, Sarada DV, Ramkumar KM. Reversibility of endothelial dysfunction in diabetes: role of polyphenols. Br J Nutr. 2016; 116(2):223–246.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Kibel A, Selthofer-Relatic K, Drenjancevic I, Bacun T, Bosnjak I, Kibel D, et al. Coronary microvascular dysfunction in diabetes mellitus. J Int Med Res. 2017; 45(6):1901–1929.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002; 39(7):1145–1150.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Isenovic ER, Soskic S, Dungen HD, Dobutovic B, Elvis T, Simone I, et al. Regulation of endothelial nitric oxide synthase in pathophysiological conditions. Cardiovasc Hematol Disord Drug Targets. 2011; 11(2):109–118.
7. Heiss EH, Dirsch VM. Regulation of eNOS enzyme activity by posttranslational modification. Curr Pharm Des. 2014; 20(22):3503–3513.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol. 2007; 42(2):271–279.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999; 443(3):285–289.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399(6736):601–605.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Greif DM, Kou R, Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry. 2002; 41(52):15845–15853.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Michell BJ, Chen Z , Tiganis T, Stapleton D, Katsis F, Power DA, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem. 2001; 276(21):17625–17628.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm. 2006; 12(4):303–309.
![crossref](/image/icon/bnr_ref_cross.gif)
14. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Heart, Lung, and Blood Institute;2004.
15. Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013; 65(2):809–848.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011; 91(6):932–944.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Song KH, Park JH, Jo I, Park JY, Seo J, Kim SA, et al. Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression. Vascul Pharmacol. 2016; 78:43–52.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Song KH, Bae SJ, Chang J, Park JH, Jo I, Cho KW, et al. Telmisartan mitigates hyperglycemia-induced vascular inflammation by increasing GSK3β-Ser9 phosphorylation in endothelial cells and mouse aortas. Biochem Biophys Res Commun. 2017; 491(4):903–911.
19. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008; 359(12):1225–1237.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372(9644):1174–1183.
21. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012; 33(7):829–837.
22. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun. 1999; 263(1):257–262.
23. Cho DH, Choi YJ, Jo SA, Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem. 2004; 279(4):2499–2506.
24. Seo J, Cho DH, Lee HJ, Sung MS, Lee JY, Won KJ, et al. Citron Rho-interacting kinase mediates arsenite-induced decrease in endothelial nitric oxide synthase activity by increasing phosphorylation at threonine 497: Mechanism underlying arsenite-induced vascular dysfunction. Free Radic Biol Med. 2016; 90:133–144.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006; 113(13):1708–1714.
26. Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, et al. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother. 2011; 12(17):2719–2735.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002; 41(21):6640–6650.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Wago T, Yoshimoto T, Akaza I, Tsuchiya K, Izumiyama H, Doi M, et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res. 2010; 33(8):796–801.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Zhang QJ, Holland WL, Wilson L, Tanner JM, Kearns D, Cahoon JM, et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes. 2012; 61(7):1848–1859.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 2002; 16(7):706–708.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Park JH, Sung HY, Lee JY, Kim HJ, Ahn JH, Jo I. B56α subunit of protein phosphatase 2A mediates retinoic acid-induced decreases in phosphorylation of endothelial nitric oxide synthase at serine 1179 and nitric oxide production in bovine aortic endothelial cells. Biochem Biophys Res Commun. 2013; 430(2):476–481.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Myojo M, Nagata D, Fujita D, Kiyosue A, Takahashi M, Satonaka H, et al. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. PLoS One. 2014; 9(5):e96948.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Obermoser V, Urban ME, Murgueitio MS, Wolber G, Kintscher U, Gust R. New telmisartan-derived PPARγ agonists: impact of the 3D-binding mode on the pharmacological profile. Eur J Med Chem. 2016; 124:138–152.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000; 28(4):149–167.
![crossref](/image/icon/bnr_ref_cross.gif)
35. Zhu G, Fujii K, Belkina N, Liu Y, James M, Herrero J, et al. Exceptional disfavor for proline at the P + 1 position among AGC and CAMK kinases establishes reciprocal specificity between them and the proline-directed kinases. J Biol Chem. 2005; 280(11):10743–10748.
36. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol. 2000; 40(12 Pt 1):1380–1390.
37. Zhang P, Zhang Y, Chen X, Li R, Yin J, Zhong D. Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels. Arzneimittelforschung. 2006; 56(8):569–573.
![crossref](/image/icon/bnr_ref_cross.gif)
38. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis. 2008; 198(1):22–28.
![crossref](/image/icon/bnr_ref_cross.gif)
39. Nakano A, Hattori Y, Aoki C, Jojima T, Kasai K. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma. Hypertens Res. 2009; 32(9):765–769.